October 26, 2026 Dragonfleye Therapeutics Corp. ("Dragonfleye" or the "Company"), a patient-centered, innovation-focused company developing minimally invasive treatments for pathologic conditions in ophthalmology using its platform technology, today announced that it completed two non-brokered private placements of common shares during 2026, raising aggregate gross proceeds of US$37.5 million (the "Offerings"). Participants included healthcare-dedicated investors and existing shareholders. Proc

Oct. 26, 2026 -- OncoHost, a technology company transforming the approach to predictive precision diagnostics for improved patient outcomes, today announced new research that was presented at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23–27 in Madrid, Spain. The study, "Plasma Proteomics Reveals the Biological Landscape of Tyrosine Kinase Inhibitors (TKI) Sensitivity in Metastatic Renal Cell Carcinoma," examines the biological basis of a model that uses

Oct. 27, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clinical trial evaluating zemprocitinib, an investigational, selective, second-generation oral Janus kinase 1 (JAK1) inhibitor, in adult patients with moderate-to-severe active rheumatoid arthritis (RA) who had experienced inadequate response or intolerance

TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability pro of systemic administration in an outpatient setting With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active

Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins (TME-EG+ phenotype), versus 4.2 months in subjects whose tumors do not (median 3 prior systemic therapies; p=0.0022) Median overall survival of 14 months in heavily pretreated TME-EG+ late-line metastatic colorectal cancer (mCRC, median 4 prior systemic therapies), including subjects with liver metastases Well tolerated, with no treatment-related serious a

With RAS-targeted therapies gaining ground in pancreatic cancer, Incyte is advancing its own contender. On Monday, the company shared what it called "encouraging" early data for its experimental KRAS G12D inhibitor INCB161734, along with two new partnerships, including one with Bristol Myers Squibb, to test the drug in separate combos against the disease. Phase I findings, presented at the European Society for Medical Oncology (ESMO) congress, showed the oral drug produced an objective response

Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study1,2 At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib1,2 No new safety signals were observed with divarasib; the most common treatment-related adverse events were mainly

Pfizer scored a green light from the FDA on Monday to move its prostate cancer combination up earlier in the treatment paradigm. The US regulator approved PARP inhibitor Talzenna (talazoparib) plus androgen receptor pathway inhibitor Xtandi (enzalutamide) for patients with homologous recombination repair (HRR) gene-mutated metastatic hormone-sensitive prostate cancer (mHSPC), also known as androgen pathway modulation-naïve or -sensitive disease. The regulatory nod expands the regimen's label, i

Oct. 26, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that a New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) has been accepted for review by the China National Medical Products Administration (NMPA). The application is proposed to be sin

Pathos AI and its Foundry platform are hitting their stride. The drug developer clinched $237 million in fresh funding on Friday while also inking a partnership with Bristol Myers Squibb and Tempus AI that will leverage Foundry's agentic AI capabilities to design better clinical trials for neurological diseases. BMS was the lead investor on Pathos' series E, which it raised at a valuation of about $3 billion — nearly double its valuation when it secured a $365-million series D last May. The fund